25Indexed trials
mesh condition
Multiple Sclerosis, Relapsing-Remitting
Intelligence
Multiple Sclerosis, Relapsing-Remitting intelligence: 25 indexed trials, 5 recruiting studies, 20 sponsors across 37 countries.
5Recruiting
20Sponsors
37Countries
Leading sponsors
Hoffmann-La Roche32 recruiting
Biogen20 recruiting
Genzyme, a Sanofi Company20 recruiting
Washington University School of Medicine21 recruiting
National Center of Neurology and Psychiatry, Japan10 recruiting
Novartis10 recruiting
Queen Mary University of London10 recruiting
Anders Svenningsson10 recruiting
Universidad de Almeria10 recruiting
University Hospital Muenster10 recruiting
University Hospital, Basel, Switzerland11 recruiting
University of Aarhus10 recruiting
Geographic activity
United States13trials
Canada8trials
United Kingdom7trials
Germany6trials
France6trials
Australia6trials
Spain6trials
Poland6trials
Belgium5trials
Italy5trials
Austria4trials
Argentina4trials
Leading interventions
Fingolimod3trials
Ocrelizumab3trials
Natalizumab2trials
Alemtuzumab 24 mg1trials
Autologous HB-adMSCs1trials
DECIMS-Wiki1trials
Antihistamine1trials
Dimethyl fumarate1trials
Domperidone1trials
Dimethyl Fumarate1trials
Fingolimod Placebo1trials
All participants will be asked to provide data and samples for collection and analysis.1trials
Methodology note
This entity is derived from structured ClinicalTrials.gov conditions and/or MeSH normalization. Counts reflect the current NeuroRisk indexed corpus and are not guaranteed exhaustive global totals.